Opportunities in the Abrysvo market are driven by unmet RSV vaccine needs, aging populations, rising RSV cases, and expanded adult immunization programs. Growth is supported by enhanced vaccine access ...

Merck MRK continues to face challenges with its second-largest product, Gardasil, which is a vaccine approved to prevent ...

We’ve spent billions chasing a dementia cure, only to hit one dead end after another. However, sometimes progress comes from ...

The American Academy of Pediatrics generally recommends RSV immunization for infants under eight months old born during or entering their first RSV season if their mothers weren’t vaccinated during ...

GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...

There are more than 900 confirmed measles cases in the United States, as of the Centers for Disease Control and Prevention’s ...

GSK (NYSE: GSK) is one of the best value stocks to buy now. On February 17, GSK released new real-world evidence showing that its RSV (respiratory syncytial virus) vaccine, Arexvy, is associated with ...

For the first time, the Arexvy® RSV vaccine, which typically costs around $300 privately, will be made available at no cost to all people aged 65 and over in residential aged care homes. This program ...

GSK plc announced new effectiveness data for its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation ...

Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse ...